Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

NASDAQ:TRVN opened at $3.74 on Friday. Trevena has a one year low of $3.35 and a one year high of $19.23. The business’s 50-day simple moving average is $3.08 and its 200 day simple moving average is $1.33. The stock has a market cap of $3.18 million, a price-to-earnings ratio of -1.40 and a beta of 1.03.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.36. The business had revenue of $0.33 million during the quarter. On average, equities research analysts predict that Trevena will post -32.25 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC acquired a new stake in Trevena, Inc. (NASDAQ:TRVN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena as of its most recent SEC filing. Institutional investors own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.